Rare Disease R&D: FDA To Use NIH Registry For Natural History Studies
Executive Summary
NIH plans to select two dozen groups to participate in a Global Rare Disease Patient Registry pilot project, which FDA hopes will lead to a better understanding of the conditions and speed drug development.
You may also be interested in...
Orphan Disease Natural History Grants Latest FDA Incentive For Drug Development
Agency will make $2m available in 2017.
As Orphan Drugs Gain More Attention, FDA Releases Development Guidance
Straightforward draft document seems aimed at entities that have limited experience working with the agency.
PDUFA V: Accelerated Approval Expansion May Outshine Rare Disease Improvements
Rare disease advocate says the focus should be on ensuring the accelerated approval expansion and surrogate endpoint guidances become FDA priorities as the rare disease drug program is set to grow under PDUFA V.